Summary
Eli Lilly & Company (LLY) has filed an 8-K report on October 30, 2024, to announce its financial results for the quarter ended September 30, 2024. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial and operational outcomes. While the 8-K itself is procedural, the attached press release will contain the substantive information investors need regarding the company's performance. This includes key metrics such as revenue, earnings per share (EPS), and updates on the company's drug pipeline and sales, particularly for its key growth drivers. Investors should carefully review Exhibit 99.1 for the specific financial figures and strategic commentary provided by the company.
Key Highlights
- 1The 8-K filing formally announces Eli Lilly's financial results for the third quarter of 2024.
- 2Key financial and operational data is detailed in an attached press release (Exhibit 99.1).
- 3The information furnished is not deemed 'filed' under Section 18 of the Exchange Act, meaning it is primarily for informational purposes.
- 4Investors are directed to Exhibit 99.1 for a comprehensive understanding of the quarterly performance.
- 5This filing serves as the official notification mechanism for the company's latest reported financial condition.